Overview

A Study of Doravirine (MK-1439) in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439-005)

Status:
Completed
Trial end date:
2012-04-10
Target enrollment:
Participant gender:
Summary
This is a study to evaluate the safety, tolerability, pharmacokinetics, and antiretroviral activity of doravirine (MK-1439) as monotherapy in antiretroviral therapy (ART)-naïve, HIV-1-infected participants.
Phase:
Phase 1
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.